Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome

X
Trial Profile

Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Prednisolone; Prednisone
  • Indications Hypereosinophilic syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
  • Most Recent Events

    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 20 May 2021 Results assessing the impact of mepolizumab on health-related quality of life, and work productivity and impairment related symptom, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 19 May 2021 Results of post-hoc analyses assessing the flare symptoms and assessed the impact of mepolizumab on flare duration in patients with hypereosinophilic syndrome, presented at the 117th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top